tolDC
Sponsors
Antwerp University Hospital, Universitair Ziekenhuis Antwerpen, Hospital Germans Trias I Pujol, Newcastle University
Conditions
Multiple SclerosisRheumatoid Arthritis
Phase 1
Phase 2
A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for Multiple Sclerosis
CompletedCTIS2024-512891-37-00
End: 2025-11-06Target: 48Updated: 2024-11-25
An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.
Not yet recruitingCTIS2025-522040-40-01
Target: 8Updated: 2026-04-20